Transaction · 0001104659-26-115551

Anderman Todd

Anderman Todd, CLO, reported an open-market or private sale at OCULAR THERAPEUTIX, INC involving 11984.000000 shares for an estimated $87363.36. Reported holdings after the transaction were 140484.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCLO
OCULOCULAR THERAPEUTIX, INC
Trade date
Oct 08, 2026
Filing date
Oct 13, 2026
View on SEC Insider profile
Estimated value-$87.3kShares × reported price
Shares traded11.9k$7.29 per share
Holdings after140kDirect
% of reported position traded7.86%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 152,468 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

OCUL price since this filing

Daily closing prices, with the filing date and available return windows
OCUL · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +57.0%1w ago +0.7%1d ago -0.1%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001104659-26-115551
Common Stock
Transaction date
Oct 08, 2026
Filed Oct 13, 2026, 09:01 PM · 5d delay
Shares
11,984 sh
$7.29 per share
Estimated value
-$87.3k
Computed from shares × price
Holdings after
140,484 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership
Filing-only score

+6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on October 7, 2024, effecting t…

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1000 to $7.4500, inclusive. The reporting person undertakes to pro…

Original filing · 0001104659-26-115551
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

OCUL